SRR934944
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 76.77398160315374
- age_years
- 24
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.575
- NOTCH_SIGNALING+0.483
- TGF_BETA_SIGNALING+0.472
- TNFA_SIGNALING_VIA_NFKB+0.439
- MYC_TARGETS_V1+0.416
- MYC_TARGETS_V2+0.412
- E2F_TARGETS+0.400
- WNT_BETA_CATENIN_SIGNALING+0.388
- INTERFERON_GAMMA_RESPONSE+0.370
- UNFOLDED_PROTEIN_RESPONSE+0.357
Top 10 suppressed
- KRAS_SIGNALING_DN-0.363
- SPERMATOGENESIS-0.302
- COAGULATION-0.261
- MYOGENESIS-0.242
- XENOBIOTIC_METABOLISM-0.227
- PANCREAS_BETA_CELLS-0.167
- FATTY_ACID_METABOLISM-0.130
- ESTROGEN_RESPONSE_LATE-0.126
- BILE_ACID_METABOLISM-0.100
- ALLOGRAFT_REJECTION-0.085
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AB522ACF-5D84-41B0-9671-CE2511EBD94F | — | — | 0.909 |
| 2 | F90967A5-96C6-4669-BCFB-0C51F539B0E7 | — | — | 0.906 |
| 3 | 67B2F9CD-759E-4300-8F4B-1B5C4F9E0B1C | — | — | 0.892 |
| 4 | SRR934863 | — | — | 0.883 |
| 5 | 4BB9587B-88CB-4BD9-BE1D-2CDF61337579 | — | — | 0.877 |
| 6 | 7E9D6B6D-3276-4240-B5C5-F3F982076358 | — | — | 0.872 |
| 7 | 798C80E6-B03A-4CB9-B0B8-DFB0DDCDA3F8 | — | — | 0.869 |
| 8 | SRR934775 | — | — | 0.868 |
| 9 | 0CEC1ADC-1E8E-4CAC-8DFD-E1A760064E58 | — | — | 0.868 |
| 10 | 745233F1-DF41-4DDA-9146-1666DD59355E | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.575 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.483 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.472 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.439 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.416 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.412 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.388 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.357 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.352 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.339 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.334 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.289 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.267 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.232 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.229 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.217 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.196 | Inavolisib | — uncovered |